Market
Company aims to evolve from early preclinical licensing to a biotech focused on clinical development Managing cash burn and risks from AOC expansion emerge as challenges

AimedBio has formally announced plans to expand its in-house clinical development and broaden its pipeline into the new antibody-oligonucleotide conjugate (AOC) modality.
In a media interview at the company’s headquarters on the 22nd, AimedBio CEO Nam-gu Heo outlined a mid- to long-term road map to build 15 clinical-stage pipeline programs by 2030, adding three each year, and secure licensing deals worth 10 trillion won.
The company has signed licensing deals totaling 3 trillion won, including a deal for AMB302, an FGFR3-targeted antibody-drug conjugate (ADC) candidate licensed to Biohaven in late 2024, and ODS025, which it licensed to Boehringer Ingelheim in 2025.
On that foundation, the company recorded four consecutive half-year periods of operating profit from the second half of 2024 through the first half of 2026. As of the first half of the year, available assets, including cash and cash equivalents and short-term financial instruments, totaled 84.2 billion won.
Until now, AimedBio has grown by using patient-derived xenograft (PDX) models of cancer tissue and its P-ADC platform, developed since its time as part of the Samsung Medical Center’s Intractable Cancer Research Project, to sell assets to partners at the preclinical stage.
By securing drug-development deals from global pharmaceutical companies based on early preclinical data, the company reduced candidate-discovery risk and established a stable stream of licensing revenue.
The next step is to reduce its reliance on licensing deals and conduct clinical trials in-house.
AMB303, an ROR1-targeted ADC candidate being co-developed with SK Plasma, uses an antibody and payload developed in-house. The company plans to submit investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) and South Korea’s Ministry of Food and Drug Safety in 2026.
The strategy is based on the calculation that an asset’s value can increase severalfold or more if the company completes proof of concept (PoC) in human phase 1 and 2 trials before negotiating a licensing deal, rather than selling it at the preclinical stage.
However, costs rise sharply once a program enters clinical development. Preclinical research can be managed at around tens of billions of won, but global phase 1 and 2 trials can require hundreds of billions to trillions of won in research and development spending for a single program.
The company’s current liquidity of more than 80 billion won may be sufficient to advance one candidate through early clinical development, but it is not enough to run 15 clinical pipeline programs simultaneously.
Unlike partnerships with companies such as Boehringer Ingelheim or Biohaven, which cover all development costs, an in-house clinical program carries the risk of a single failure directly damaging the company’s financial position.
Expansion of the AOC platform, which conjugates RNA to antibodies to extend into areas such as brain disorders and other central nervous system (CNS) conditions, is also a variable.
ADC platforms have been validated to some extent through the commercial success of drugs such as Enhertu, but AOCs remain a challenging modality at an early stage even in the global market.
Securing a blood-brain barrier (BBB)-penetrating shuttle platform and validating the delivery efficiency and safety of gene-regulating agents require research capabilities different from those used to develop existing ADC cancer drugs.
Follow-up clinical results for previously licensed pipeline programs also remain to be seen. In Biohaven’s ongoing global phase 1 trial of AMB302, a signal of tumor shrinkage has been observed, while ODS025 has reached the first-patient-dosed stage of a global phase 1 trial.
However, it remains uncertain whether the candidates can maintain efficacy against competing drugs in larger cohorts, beyond early safety and tolerability measures. Whether the strong predictive performance seen in preclinical studies can be replicated in human trials will be a key measure of the sustainability of milestone payments at each stage.
For AimedBio to establish itself as a full-fledged biotech conducting its own clinical development, rather than a venture specializing in preclinical licensing, observers will be watching the pace of actual clinical entry after AMB303 receives IND approval and whether concrete data validate its AOC pipeline.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
Medtronic to Acquire Contego Medical for $380 Million, Strengthening Carotid Treatment Portfolio

AstraZeneca wins Soliris antitrust lawsuit, with court finding no patent abuse

Alphabet Subsidiary Isomorphic Raises $5 Billion for AI Drug Development

Google Subsidiary Isomorphic Raises Another $5 Billion in Funding in Six Months

Lilly invests $7.9 billion in cancer-targeting technology company in fourth deal in 6 weeks

Samsung Biologics Completes 2.665 Trillion Won Rights Offering; New Shares to List Nov. 30